8-K Announcements
6Material company update
May 21, 2026·SEC
Material company update
May 19, 2026·SEC
Material company update
May 14, 2026·SEC
AIM ImmunoTech Inc.(AIM)Earnings, Financials & Key Ratios
AIM•AMEX
$0.31
Price updated Jun 27, 2026
AboutAIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's products include Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, prostate and pancreatic cancer, myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat genital warts, a sexually transmitted disease. It has agreements with UMN Pharma Inc.; Japanese National Institute of Infectious Diseases; Shionogi & Co., Ltd.; Polysciences Inc.; and University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.Show more
- Revenue$88K-48.2%
- EBITDA-$10M+47.2%
- Net Income-$14M+19.4%
- EPS (Diluted)-8.62+23.2%
- Gross Margin-284.09%-447.4%
- EBITDA Margin-11722.73%-2.1%
- Operating Margin-11961.36%-2.8%
- Net Margin-15861.36%-55.7%
AIM Price & Volume
AIM ImmunoTech Inc. (AIM) stock price & volume — 10-year historical chart
Loading chart...
Persistent Operational Losses Threaten AIM Liquidity Position
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial Position:Vulnerable
Cash Flow:Burning
Primary Risk:Imminent liquidity exhaustion
"AIM ImmunoTech faces a precarious outlook characterized by negligible quarterly revenue of $22,000 and a persistent inability to achieve operational scale. The company's reliance on R&D spending, which totaled $482,000 in 2026Q1, continues to erode shareholder equity, now standing at a deficit of $443.8 million in accumulated losses. Investors should monitor the imminent liquidity risk, as the current cash position of $5.8 million remains insufficient to support the company's ongoing clinical development programs without further dilutive financing."
Verdict Logic
the company's inability to generate meaningful revenue, coupled with a 2026Q1 net loss of $3.0 million, suggests an unsustainable financial trajectory that poses a high risk of further shareholder dilution.
AIM Growth Metrics
AIM ImmunoTech Inc. (AIM) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-4.05%
5 Years-11.6%
3 Years-14.54%
TTM-35.62%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM12.7%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM79.82%
Return on Capital
10 Years-108.93%
5 Years-148.87%
3 Years-265.73%
Last Year-
AIM Recent Earnings
AIM ImmunoTech Inc. (AIM) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 4/12 qtrs (33%)●Beat Revenue 4/12 qtrs (44%)
Q2 2026Latest
May 15, 2026Metric
Actual
Est
EPS
$0.69-86.5%
$0.37
Rev
$22,000+0.0%
$22,000
Q2 2026
Mar 27, 2026Metric
Actual
Est
EPS
$0.44+53.2%
$0.94
Rev
$21,000-79.0%
$100,000
Q4 2025
Nov 17, 2025Metric
Actual
Est
EPS
$1.57-61.0%
$0.97
Rev
$26,000
—
Q3 2025
Aug 14, 2025Metric
Actual
Est
EPS
$3.68+54.0%
$8.00
Rev
$25,000-75.0%
$100,000
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 15, 2026 | $0.69vs $0.37-86.5% | $22,000vs $22,000+0.0% |
| Q2 2026 | Mar 27, 2026 | $0.44vs $0.94+53.2% | $21,000vs $100,000-79.0% |
| Q4 2025 | Nov 17, 2025 | $1.57vs $0.97-61.0% | $26,000 |
| Q3 2025 | Aug 14, 2025 | $3.68vs $8.00+54.0% | $25,000vs $100,000-75.0% |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for AIM ImmunoTech Inc. (AIM)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.31 | $1.06M | -0.04 | -48.24% | -15861.36% | — | — | |
| $0.39 | $57.55M | -1.35 | 31.28% | -998.18% | -84.55% | — | |
| $63.65 | $1.24B | -6.54 | -43.89% | -284.18% | -87% | — | |
| $4.25 | $1.52B | -3.90 | 60.6% | -123.9% | -50.17% | — | |
| $1.10 | $760.12M | -0.61 | -69.99% | — | -666.47% | — | |
| $8.88 | $1.46B | 3.50 | 64.69% | -14.73% | — | — |
Compare AIM vs Peers
AIM ImmunoTech Inc. (AIM) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
AIM SEC Filings & Documents
AIM ImmunoTech Inc. (AIM) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when AIM posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
AIM Frequently Asked Questions
AIM ImmunoTech Inc. (AIM) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is AIM ImmunoTech Inc.'s revenue?
AIM ImmunoTech Inc. (AIM) reported $0.1M in revenue for fiscal year 2025. This represents a 6% decrease from $0.1M in 1996.
How fast is AIM ImmunoTech Inc. growing?
AIM ImmunoTech Inc. (AIM) saw revenue decline by 48.2% over the past year.
Is AIM profitable?
AIM ImmunoTech Inc. (AIM) reported a net loss of $13.3M for fiscal year 2025.
Dividend & Returns
What is AIM ImmunoTech Inc.'s free cash flow?
AIM ImmunoTech Inc. (AIM) had negative free cash flow of $11.6M in fiscal year 2025, likely due to heavy capital investments.